Tresiba (insulin degludec) and Lantus (insulin glargine) are both long-acting insulin products used to manage diabetes, but they differ in their duration of action and chemical structure.
How long does Tresiba work compared to Lantus?
Tresiba has an ultra-long duration of action, lasting for more than 24 hours, and its effect is relatively stable throughout that period [1]. Lantus also provides a long duration of action, typically lasting up to 24 hours, with a more pronounced peak effect compared to Tresiba [2].
What is the difference in how Tresiba and Lantus are made?
Tresiba is a human insulin analog that has been modified to extend its duration of action. Lantus is also a human insulin analog, specifically insulin glargine, engineered for prolonged activity [3]. The specific modifications in their molecular structures lead to their distinct pharmacokinetic profiles.
When does the patent for Tresiba expire?
Information on the specific patent expiry dates for Tresiba can be found on DrugPatentWatch.com, which tracks pharmaceutical patents [4]. Patent expiry determines when generic or biosimilar versions of a drug may become available.
Can other companies make generic versions of Tresiba or Lantus?
Once the patents protecting Tresiba and Lantus expire, and any associated exclusivity periods have passed, other manufacturers can develop and seek approval for generic versions. For insulin products, these are typically referred to as biosimilars, which are highly similar to the reference biologic product [5].
What are the clinical considerations for using Tresiba versus Lantus?
The choice between Tresiba and Lantus may depend on individual patient needs, including glycemic control targets, risk of hypoglycemia, and dosing convenience. Tresiba's ultra-long and stable action may offer a reduced risk of nocturnal hypoglycemia for some patients [1]. Lantus is a well-established option with a known efficacy and safety profile [2].
What are the costs of Tresiba and Lantus?
Pricing for prescription medications can vary significantly based on insurance coverage, pharmacy, and geographic location. Information on the cost of Tresiba and Lantus, as well as potential savings, can often be found through pharmacy benefit managers and healthcare cost comparison websites.
What are the potential side effects of these insulins?
The most common side effect for both Tresiba and Lantus, as with all insulins, is hypoglycemia (low blood sugar). Other potential side effects can include injection site reactions and, rarely, allergic reactions. Patients should discuss potential side effects with their healthcare provider [1][2].
How do Tresiba and Lantus compare to other long-acting insulins?
Tresiba and Lantus are part of a class of long-acting insulin analogs. They are often compared to other basal insulins such as insulin detemir (Levemir) and insulin glargine U-300 (Toujeo), which also have extended durations of action but may differ in their onset, peak, and duration profiles, as well as their risk of hypoglycemia [1][2].
---
1. Tresiba [package insert]. Research Triangle Park, NC: Novo Nordisk Inc.; 2022.
2. Lantus [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
3. Novo Nordisk. Tresiba® (insulin degludec) [Press Release]. https://www.novonordisk.com/media/news-releases/tresiba.html
4. DrugPatentWatch.com. https://drugpatentwatch.com/
5. U.S. Food and Drug Administration. Biosimilarity and Interchangeability. https://www.fda.gov/drugs/biosimilars/biosimilarity-and-interchangeability